Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

  1. Lau, G.
  2. Abou-Alfa, G.K.
  3. Cheng, A.-L.
  4. Sukeepaisarnjaroen, W.
  5. Van Dao, T.
  6. Kang, Y.K.
  7. Thungappa, S.C.
  8. Kudo, M.
  9. Sangro, B.
  10. Kelley, R.K.
  11. Furuse, J.
  12. Park, J.-W.
  13. Sunpaweravong, P.
  14. Fasolo, A.
  15. Yau, T.
  16. Kawaoka, T.
  17. Azevedo, S.
  18. Reig, M.
  19. Assenat, E.
  20. Yarchoan, M.
  21. He, A.R.
  22. Makowsky, M.
  23. Gupta, C.
  24. Negro, A.
  25. Chan, S.L.
Revista:
Journal of Hepatology

ISSN: 1600-0641,  0168-8278

Ano de publicación: 2024

Tipo: Artigo

DOI: 10.1016/J.JHEP.2024.07.017 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus